

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
05 December 2024 (05.12.2024)



(10) International Publication Number
WO 2024/246841 A2

(51) International Patent Classification:

A61K 9/00 (2006.01) A61K 31/7056 (2006.01)
A61K 9/16 (2006.01) A61K 31/22 (2006.01)

(21) International Application Number:

PCT/IB2024/055318

(22) International Filing Date:

30 May 2024 (30.05.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/470,161	31 May 2023 (31.05.2023)	US
63/525,228	06 July 2023 (06.07.2023)	US
63/633,277	12 April 2024 (12.04.2024)	US

(71) Applicant: **TAKEDA PHARMACEUTICAL COMPANY LIMITED** [JP/JP]; 1-1, Doshomachi 4-chome, Chuoku, Osaka-shi, Osaka 051-0045 (JP).

(72) Inventor: **SUEDA, Katsuhiko**; c/o Shire Human Genetic Therapies, Inc., 300 Shire Way, Lexington, Massachusetts 02421 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: MARIBAVIR COMPOSITIONS AND USES THEREOF

(57) Abstract: The present disclosure provides novel methods and compositions for using maribavir in the treatment of pediatric and adolescent patient populations. The present disclosure also provides compositions of maribavir in the form of a powder for oral suspension, which are useful for patients with difficulty swallowing pills, including pediatric and adolescent patient populations.



WO 2024/246841 A2